Valeant’s Permax withdrawn
Valeant Pharmaceuticals will voluntarily withdraw its Parkinson's disease therapy Permax (pergolide) due to the high rate of heart valve damage associated with the drug, FDA announces March 29. The agency requested the withdrawal due to results of two studies published in the January issue of the New England Journal of Medicine that showed a five-fold increase in the risk of valvulopathy. Generic versions of Permax, marketed by Par and Teva, will also be withdrawn...
You may also be interested in...
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
In this week’s podcast, Medtech Insight's managing editor Marion Webb and deputy editor Reed Miller discuss highlights from the recent J.P. Morgan Healthcare and North American Neuromodulation Society (NANS) virtual meetings. London, UK-based reporter Barnaby Pickering profiles start-up CorWave SA, which developed a left ventricular assist device for treating end-stage heart failure.
Tom McLain tells how the new MCIT policy from the US Medicare agency – and winning support from Congress – will guarantee Medicare coverage for his company’s product, an artificial intelligence-enabled in vitro diagnostic platform.